Indaptus Therapeutics First Patient Received Multiple Doses Of Decoy20, The Company's Broad-Based, "Pulse-Prime" Immuno-Oncology Therapy For Advanced Solid Tumors

• First-in-human trial confirms "Pulse-Prime" hypothesis targeting stimulation of innate and adaptive immune systems
• Investigational package of broad immune agonists derived from Gram-negative bacteria which induces dozens of cytokines/chemokines that are quickly cleared from the body
• Identification of tolerable single dose in Phase 1a, recommended for multi-dosing, will be presented at ASCO
  
   

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the successful advancement of its Phase 1 trial for Decoy20, an investigational novel package of broad immune agonists for cancer immunotherapy that has first-in-class potential across a diverse range of cancers including liver, pancreatic, colorectal and non-small cell lung.